Denali Therapeutics Inc. (DNLI)
NASDAQ: DNLI · Real-Time Price · USD
20.23
-0.31 (-1.51%)
Apr 21, 2026, 1:53 PM EDT - Market open
Denali Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
503
Market Cap
3.21B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 330.53M | 222.07M | 204.74% |
| Dec 31, 2022 | 108.46M | 59.80M | 122.90% |
| Dec 31, 2021 | 48.66M | -287.00M | -85.50% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Telix Pharmaceuticals | 803.79M |
| Catalyst Pharmaceuticals | 588.99M |
| Arcutis Biotherapeutics | 376.07M |
| Arcus Biosciences | 247.00M |
| Beam Therapeutics | 139.74M |
| Alumis | 24.05M |
| Relay Therapeutics | 15.36M |
DNLI News
- 15 days ago - Takeda Exits Dementia Drug Partnership With Denali Therapeutics - Here's Why - Benzinga
- 18 days ago - Denali Therapeutics Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN) - GlobeNewsWire
- 27 days ago - Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II) - GlobeNewsWire
- 6 weeks ago - FDA reversals leave investors worrying about the fates of other experimental drugs - CNBC
- 7 weeks ago - Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights - GlobeNewsWire
- 2 months ago - Denali Therapeutics Presents Enzyme TransportVehicle™ Progress Across Three Clinical Programs for Treatment of Lysosomal Storage Disorders at 2026 WORLDSymposium™ - GlobeNewsWire
- 2 months ago - Denali Therapeutics To Host Webcast Highlighting Presentations on Enzyme TransportVehicle™ Programs at the 2026 WORLDSymposium™ - GlobeNewsWire
- 2 months ago - Denali Therapeutics Announces Data Presentations on Enzyme TransportVehicle™ Programs for Hunter Syndrome, Sanfilippo Syndrome Type A and Pompe Disease at Upcoming 2026 WORLDSymposium™ - GlobeNewsWire